[1]	NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANTS PARK8 VAL-1122; CYS-1441; CYS-1699 AND THR-2020. TISSUE=Brain; DOI=10.1016/j.neuron.2004.11.005; PubMed=15541309 [NCBI, ExPASy, EBI, Israel, Japan] Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S.J., Kachergus J.M., Hulihan M.M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carballo Carbajal I., Vieregge P., Asmus F., Mueller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T.; "Mutations in a large multifunctional protein (LRRK2) cause autosomal dominant parkinsonism with pleiomorphic a-synuclein and tau-pathology (PARK8)."; Neuron 44:601-607(2004).
[2]	NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). DOI=10.1038/ng1285; PubMed=14702039 [NCBI, ExPASy, EBI, Israel, Japan] Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.; "Complete sequencing and characterization of 21,243 full-length human cDNAs."; Nat. Genet. 36:40-45(2004).
[3]	NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2128-2527 (ISOFORM 1). TISSUE=Testis; DOI=10.1186/1471-2164-8-399; PubMed=17974005 [NCBI, ExPASy, EBI, Israel, Japan] Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., Wellenreuther R., Mehrle A., Schuster C., Bahr A., Blocker H., Heubner D., Hoerlein A., Michel G., Wedler H., Kohrer K., Ottenwalder B., Poustka A., Wiemann S., Schupp I.; "The full-ORF clone resource of the German cDNA consortium."; BMC Genomics 8:399-399(2007).
[4]	DISEASE. DOI=10.1093/brain/awh607; PubMed=16081470 [NCBI, ExPASy, EBI, Israel, Japan] Adams J.R., van Netten H., Schulzer M., Mak E., McKenzie J., Strongosky A., Sossi V., Ruth T.J., Lee C.S., Farrer M., Gasser T., Uitti R.J., Calne D.B., Wszolek Z.K., Stoessl A.J.; "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation."; Brain 128:2777-2785(2005).
[5]	SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANT PARK8 THR-2020. DOI=10.1093/hmg/ddi439; PubMed=16321986 [NCBI, ExPASy, EBI, Israel, Japan] Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., Ueffing M.; "The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity."; Hum. Mol. Genet. 15:223-232(2006).
[6]	DISEASE. DOI=10.1016/j.mad.2005.06.010; PubMed=16087219 [NCBI, ExPASy, EBI, Israel, Japan] Toft M., Sando S.B., Melquist S., Ross O.A., White L.R., Aasly J.O., Farrer M.J.; "LRRK2 mutations are not common in Alzheimer's disease."; Mech. Ageing Dev. 126:1201-1205(2005).
[7]	SUBCELLULAR LOCATION, AND CHARACTERIZATION OF VARIANTS PD CYS-1441 AND SER-2019. DOI=10.1073/pnas.0507360102; PubMed=16269541 [NCBI, ExPASy, EBI, Israel, Japan] West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M.; "Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity."; Proc. Natl. Acad. Sci. U.S.A. 102:16842-16847(2005).
[8]	SUBCELLULAR LOCATION, INTERACTION WITH PARK2, AND POSSIBLE FUNCTION. DOI=10.1073/pnas.0508052102; PubMed=16352719 [NCBI, ExPASy, EBI, Israel, Japan] Smith W.W., Pei Z., Jiang H., Moore D.J., Liang Y., West A.B., Dawson V.L., Dawson T.M., Ross C.A.; "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal degeneration."; Proc. Natl. Acad. Sci. U.S.A. 102:18676-18681(2005).
[9]	TISSUE SPECIFICITY. DOI=10.1002/ana.20808; PubMed=16532471 [NCBI, ExPASy, EBI, Israel, Japan] Galter D., Westerlund M., Carmine A., Lindqvist E., Sydow O., Olson L.; "LRRK2 expression linked to dopamine-innervated areas."; Ann. Neurol. 59:714-719(2006).
[10]	VARIANTS PARK8 GLY-1441 AND CYS-1699, AND TISSUE SPECIFICITY. DOI=10.1016/j.neuron.2004.10.023; PubMed=15541308 [NCBI, ExPASy, EBI, Israel, Japan] Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N.L., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A.J., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B.; "Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease."; Neuron 44:595-600(2004).
[11]	VARIANT PARK8/PD SER-2019. DOI=10.1086/429256; PubMed=15726496 [NCBI, ExPASy, EBI, Israel, Japan] Kachergus J.M., Mata I.F., Hulihan M., Taylor J.P., Lincoln S., Aasly J.O., Gibson J.M., Ross O.A., Lynch T., Wiley J., Payami H., Nutt J., Maraganore D.M., Czyzewski K., Styczynska M., Wszolek Z.K., Farrer M.J., Toft M.; "Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations."; Am. J. Hum. Genet. 76:672-680(2005).
[12]	VARIANT PARK8 SER-2019. DOI=10.1002/ana.20401; PubMed=15732108 [NCBI, ExPASy, EBI, Israel, Japan] Hernandez D.G., Paisan-Ruiz C., McInerney-Leo A., Jain S., Meyer-Lindenberg A., Evans E.W., Berman K.F., Johnson J., Auburger G., Schaeffer A.A., Lopez G.J., Nussbaum R.L., Singleton A.B.; "Clinical and positron emission tomography of Parkinson's disease caused by LRRK2."; Ann. Neurol. 57:453-456(2005).
[13]	VARIANT PARK8/PD SER-2019. DOI=10.1002/ana.20456; PubMed=15852371 [NCBI, ExPASy, EBI, Israel, Japan] Aasly J.O., Toft M., Fernandez-Mata I., Kachergus J.M., Hulihan M., White L.R., Farrer M.J.; "Clinical features of LRRK2-associated Parkinson's disease in central Norway."; Ann. Neurol. 57:762-765(2005).
[14]	VARIANT PARK8 SER-2019. DOI=10.1002/ana.20636; PubMed=16240353 [NCBI, ExPASy, EBI, Israel, Japan] French Parkinson's disease genetics study group; Lesage S., Ibanez P., Lohmann E., Pollak P., Tison F., Tazir M., Leutenegger A.-L., Guimaraes J., Bonnet A.-M., Agid Y., Duerr A., Brice A.; "G2019S LRRK2 mutation in French and North African families with Parkinson's disease."; Ann. Neurol. 58:784-787(2005).
[15]	VARIANT PARK8 THR-2020. DOI=10.1002/ana.20484; PubMed=15880653 [NCBI, ExPASy, EBI, Israel, Japan] Funayama M., Hasegawa K., Ohta E., Kawashima N., Komiyama M., Kowa H., Tsuji S., Obata F.; "An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family."; Ann. Neurol. 57:918-921(2005).
[16]	VARIANT PD SER-2019. DOI=10.1002/ana.20510; PubMed=15929036 [NCBI, ExPASy, EBI, Israel, Japan] Deng H., Le W., Guo Y., Hunter C.B., Xie W., Jankovic J.; "Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation."; Ann. Neurol. 57:933-934(2005).
[17]	VARIANTS PARK8 MET-793; ARG-930; CYS-1096 THR-1228; SER-2019 AND THR-2020, AND VARIANT LYS-551. DOI=10.1093/brain/awh666; PubMed=16251215 [NCBI, ExPASy, EBI, Israel, Japan] Berg D., Schweitzer K., Leitner P., Zimprich A., Lichtner P., Belcredi P., Bruessel T., Schulte C., Maass S., Naegele T.; "Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease."; Brain 128:3000-3011(2005).
[18]	VARIANTS PARK8 CYS-1699; HIS-1941; SER-2019 AND ILE-2356. DOI=10.1093/brain/awh667; PubMed=16272164 [NCBI, ExPASy, EBI, Israel, Japan] Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P.M., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W.; "Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data."; Brain 128:2786-2796(2005).
[19]	VARIANTS PD VAL-1371; CYS-1441 AND SER-2019. DOI=10.1038/sj.ejhg.5201539; PubMed=16333314 [NCBI, ExPASy, EBI, Israel, Japan] Di Fonzo A., Tassorelli C., De Mari M., Chien H.F., Ferreira J., Rohe C.F., Riboldazzi G., Antonini A., Albani G., Mauro A., Marconi R., Abbruzzese G., Lopiano L., Fincati E., Guidi M., Marini P., Stocchi F., Onofrj M., Toni V., Tinazzi M., Fabbrini G., Lamberti P., Vanacore N., Meco G., Leitner P., Uitti R.J., Wszolek Z.K., Gasser T., Simons E.J., Breedveld G.J., Goldwurm S., Pezzoli G., Sampaio C., Barbosa E., Martignoni E., Oostra B.A., Bonifati V.; "Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease."; Eur. J. Hum. Genet. 14:322-331(2006).
[20]	VARIANT PARK8 SER-2019. DOI=10.1136/jmg.2005.035568; PubMed=16272257 [NCBI, ExPASy, EBI, Israel, Japan] Goldwurm S., Di Fonzo A., Simons E.J., Rohe C.F., Zini M., Canesi M., Tesei S., Zecchinelli A., Antonini A., Mariani C., Meucci N., Sacilotto G., Sironi F., Salani G., Ferreira J., Chien H.F., Fabrizio E., Vanacore N., Dalla Libera A., Stocchi F., Diroma C., Lamberti P., Sampaio C., Meco G., Barbosa E., Bertoli-Avella A.M., Breedveld G.J., Oostra B.A., Pezzoli G., Bonifati V.; "The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor."; J. Med. Genet. 42:E65-E65(2005).
[21]	VARIANT PD SER-2019. DOI=10.1016/S0140-6736(05)17828-3; PubMed=15680455 [NCBI, ExPASy, EBI, Israel, Japan] The Parkinson study group-PROGENI investigators; Nichols W.C., Pankratz N., Hernandez D., Paisan-Ruiz C., Jain S., Halter C.A., Michaels V.E., Reed T., Rudolph A., Shults C.W., Singleton A., Foroud T.; "Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease."; Lancet 365:410-412(2005).
[22]	VARIANT PARK8 SER-2019. DOI=10.1016/S0140-6736(05)17829-5; PubMed=15680456 [NCBI, ExPASy, EBI, Israel, Japan] The Italian Parkinson genetics network; Di Fonzo A., Rohe C.F., Ferreira J., Chien H.F., Vacca L., Stocchi F., Guedes L., Fabrizio E., Manfredi M., Vanacore N., Goldwurm S., Breedveld G.J., Sampaio C., Meco G., Barbosa E., Oostra B.A., Bonifati V.; "A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease."; Lancet 365:412-415(2005).
[23]	VARIANT PD SER-2019. DOI=10.1016/S0140-6736(05)17830-1; PubMed=15680457 [NCBI, ExPASy, EBI, Israel, Japan] Gilks W.P., Abou-Sleiman P.M., Gandhi S., Jain S., Singleton A., Lees A.J., Shaw K., Bhatia K.P., Bonifati V., Quinn N.P., Lynch J.M., Healy D.G., Holton J.L., Revesz T., Wood N.W.; "A common LRRK2 mutation in idiopathic Parkinson's disease."; Lancet 365:415-416(2005).
[24]	VARIANT PD SER-2019. DOI=10.1016/S0140-6736(05)74809-1; PubMed=15811454 [NCBI, ExPASy, EBI, Israel, Japan] Toft M., Mata I.F., Kachergus J.M., Ross O.A., Farrer M.J.; "LRRK2 mutations and Parkinsonism."; Lancet 365:1229-1230(2005).
[25]	VARIANT SER-2019. DOI=10.1002/mds.20618; PubMed=16001413 [NCBI, ExPASy, EBI, Israel, Japan] Kay D.M., Kramer P., Higgins D.S., Zabetian C.P., Payami H.; "Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation."; Mov. Disord. 20:1077-1078(2005).
[26]	VARIANT PD SER-2019. DOI=10.1002/mds.20751; PubMed=16250030 [NCBI, ExPASy, EBI, Israel, Japan] Kay D.M., Zabetian C.P., Factor S.A., Nutt J.G., Samii A., Griffith A., Bird T.D., Kramer P., Higgins D.S., Payami H.; "Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics."; Mov. Disord. 21:519-523(2006).
[27]	VARIANTS PARK8 CYS-1441; GLY-1441; HIS-1441; GLN-1514; SER-1542; GLU-1598; CYS-1699; THR-1869; THR-2012; SER-2019; THR-2020 AND ARG-2385, AND VARIANTS PRO-119; LYS-551; VAL-723; MET-793; VAL-1122; ALA-1262; HIS-1398; PRO-1628; THR-1646; THR-1647; ASP-2081; LEU-2119; ILE-2261 AND THR-2397. DOI=10.1007/s10048-005-0005-1; PubMed=16172858 [NCBI, ExPASy, EBI, Israel, Japan] Mata I.F., Kachergus J.M., Taylor J.P., Lincoln S., Aasly J., Lynch T., Hulihan M.M., Cobb S.A., Wu R.-M., Lu C.-S., Lahoz C., Wszolek Z.K., Farrer M.J.; "Lrrk2 pathogenic substitutions in Parkinson's disease."; Neurogenetics 6:171-177(2005).
[28]	VARIANTS PARK8 VAL-1371 AND SER-2019, AND VARIANTS HIS-1398 AND THR-2397. DOI=10.1212/01.WNL.0000167552.79769.b3; PubMed=16157901 [NCBI, ExPASy, EBI, Israel, Japan] Paisan-Ruiz C., Lang A.E., Kawarai T., Sato C., Salehi-Rad S., Fisman G.K., Al-Khairallah T., St George-Hyslop P.H., Singleton A., Rogaeva E.; "LRRK2 gene in Parkinson disease: mutation analysis and case control association study."; Neurology 65:696-700(2005).
[29]	VARIANT PD GLN-1067. DOI=10.1212/01.wnl.0000180517.70572.37; PubMed=16247070 [NCBI, ExPASy, EBI, Israel, Japan] Skipper L., Shen H., Chua E., Bonnard C., Kolatkar P., Tan L.C.S., Jamora R.D., Puvan K., Puong K.Y., Zhao Y., Pavanni R., Wong M.C., Yuen Y., Farrer M., Liu J.J., Tan E.K.; "Analysis of LRRK2 functional domains in nondominant Parkinson disease."; Neurology 65:1319-1321(2005).
[30]	VARIANTS PD MET-793; THR-1869 AND SER-2019. DOI=10.1212/01.WNL.0000169023.51764.b0; PubMed=16157908 [NCBI, ExPASy, EBI, Israel, Japan] Farrer M., Stone J., Mata I.F., Lincoln S., Kachergus J., Hulihan M., Strain K.J., Maraganore D.M.; "LRRK2 mutations in Parkinson disease."; Neurology 65:738-740(2005).
[31]	VARIANTS PD CYS-1441; HIS-1441 AND SER-2019. DOI=10.1212/01.WNL.0000172630.22804.73; PubMed=16157909 [NCBI, ExPASy, EBI, Israel, Japan] Zabetian C.P., Samii A., Mosley A.D., Roberts J.W., Leis B.C., Yearout D., Raskind W.H., Griffith A.; "A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations."; Neurology 65:741-744(2005).
[32]	VARIANT PD GLY-1441. DOI=10.1016/j.neulet.2005.03.033; PubMed=15925109 [NCBI, ExPASy, EBI, Israel, Japan] Mata I.F., Taylor J.P., Kachergus J., Hulihan M., Huerta C., Lahoz C., Blazquez M., Guisasola L.M., Salvador C., Ribacoba R., Martinez C., Farrer M., Alvarez V.; "LRRK2 R1441G in Spanish patients with Parkinson's disease."; Neurosci. Lett. 382:309-311(2005).
[33]	VARIANT PARK8/PD SER-2019. DOI=10.1016/j.neulet.2005.10.083; PubMed=16298482 [NCBI, ExPASy, EBI, Israel, Japan] Infante J., Rodriguez E., Combarros O., Mateo I., Fontalba A., Pascual J., Oterino A., Polo J.M., Leno C., Berciano J.; "LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease."; Neurosci. Lett. 395:224-226(2006).
[34]	VARIANT PD SER-2019. DOI=10.1016/j.parkreldis.2005.05.004; PubMed=16102999 [NCBI, ExPASy, EBI, Israel, Japan] Gosal D., Ross O.A., Wiley J., Irvine G.B., Johnston J.A., Toft M., Mata I.F., Kachergus J., Hulihan M., Taylor J.P., Lincoln S.J., Farrer M.J., Lynch T., Mark Gibson J.; "Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD."; Parkinsonism Relat. Disord. 11:349-352(2005).
[35]	VARIANTS PD CYS-1441; GLY-1441 AND SER-2019. DOI=10.1001/archneur.63.3.377; PubMed=16533964 [NCBI, ExPASy, EBI, Israel, Japan] Gaig C., Ezquerra M., Marti M.J., Munoz E., Valldeoriola F., Tolosa E.; "LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance."; Arch. Neurol. 63:377-382(2006).
[36]	CHARACTERIZATION OF VARIANT ARG-2385, AND ASSOCIATION WITH PARKINSON DISEASE. DOI=10.1007/s00439-006-0268-0; PubMed=17019612 [NCBI, ExPASy, EBI, Israel, Japan] Tan E.K., Zhao Y., Skipper L., Tan M.G., Di Fonzo A., Sun L., Fook-Chong S., Tang S., Chua E., Yuen Y., Tan L., Pavanni R., Wong M.C., Kolatkar P., Lu C.S., Bonifati V., Liu J.J.; "The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence."; Hum. Genet. 120:857-863(2007).
[37]	VARIANTS [LARGE SCALE ANALYSIS] PRO-119; VAL-419; LYS-551; VAL-723; HIS-1398; GLN-1514; SER-1542; GLN-1550 AND PRO-1723. DOI=10.1038/nature05610; PubMed=17344846 [NCBI, ExPASy, EBI, Israel, Japan] Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.; "Patterns of somatic mutation in human cancer genomes."; Nature 446:153-158(2007).
[38]	VARIANTS PD VAL-712; LEU-1728; HIS-1728; SER-2019; MET-2141; HIS-2143 AND HIS-2466, AND VARIANTS SER-228; VAL-716; GLU-871; PHE-1870 AND LYS-2395. DOI=10.1002/humu.20668; PubMed=18213618 [NCBI, ExPASy, EBI, Israel, Japan] Paisan-Ruiz C., Nath P., Washecka N., Gibbs J.R., Singleton A.B.; "Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls."; Hum. Mutat. 29:485-490(2008).

Comments

FUNCTION: Probable protein kinase whose role is not yet known. May play a role in the phosphorylation of proteins central to Parkinson disease. May also have GTPase activity.
CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
SUBUNIT: Interacts with PARK2.
SUBCELLULAR LOCATION: Cytoplasm. Membrane; Peripheral membrane protein. Note=Localized in the cytoplasm and associated with cellular membrane structures. Associates with the mitochondrial outer membrane.

ALTERNATIVE PRODUCTS: 2 named isoforms [FASTA] produced by alternative splicing.

Name	1
Isoform ID	Q5S007-1
This is the isoform sequence displayed in this entry.

Name	2
Isoform ID	Q5S007-2
Note: May be due to intron retention. No experimental confirmation available.
Features which should be applied to build the isoform sequence: VSP_036140, VSP_036141, VSP_036142.

TISSUE SPECIFICITY: Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.
DISEASE: Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8) [MIM:607060, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.
SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
SIMILARITY: Contains 16 LRR (leucine-rich) repeats.
SIMILARITY: Contains 1 protein kinase domain.
SIMILARITY: Contains 1 Roc domain.
WEB RESOURCE: Name=GeneReviews; URL="http://www.genetests.org/query?gene=LRRK2";.

Copyright

Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.

Cross-references

Sequence databases

EMBL

AY792511; AAV63975.1; -; mRNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]
AK127729; -; NOT_ANNOTATED_CDS; mRNA.	[EMBL / GenBank / DDBJ]
AL834529; CAD39185.1; -; mRNA.	[EMBL / GenBank / DDBJ] [CoDingSequence]

IPI

IPI00175649; -.
IPI00794835; -.

RefSeq

NP_940980.3; -.

UniGene

Hs.187636

3D structure databases

PDB

2ZEJ; X-ray; 2.00 A; A/B=1333-1516.	[ExPASy / RCSB / EBI]
3D6T; X-ray; 2.43 A; B=1336-1505.	[ExPASy / RCSB / EBI]

Detailed list of linked structures.

2ZEJ; -.
3D6T; -.

PTM databases

Q5S007; -.

Enzyme and pathway databases

BRENDA

2.7.11.1; 247.

Organism-specific databases

GC12P038908; -.

HIX0010547; -.

HGNC:18618; LRRK2.

HPA014293; -.

168600; phenotype. [NCBI / EBI]
607060; phenotype. [NCBI / EBI]
609007; gene. [NCBI / EBI]

Orphanet

2828; Parkinson disease, genetic types.

PharmGKB

PA134968052; -.

Gene expression databases

Q5S007; -.

Q5S007; -.

HS_LRRK2; -.

ENSG00000188906; Homo sapiens.

Ontologies

GO:0032473;	Cellular component: external side of mitochondrial outer membrane (inferred from direct assay from UniProtKB).
GO:0005624;	Cellular component: membrane fraction (inferred from direct assay from UniProtKB).
GO:0005524;	Molecular function: ATP binding (inferred by curator from UniProtKB).
GO:0005525;	Molecular function: GTP binding (inferred from direct assay from UniProtKB).
GO:0034211;	Molecular function: GTP-dependent protein kinase activity (inferred from mutant phenotype from UniProtKB).
GO:0005096;	Molecular function: GTPase activator activity (inferred from direct assay from UniProtKB).
GO:0042803;	Molecular function: protein homodimerization activity (inferred from physical interaction from UniProtKB).
GO:0000165;	Biological process: MAPKKK cascade (inferred from direct assay from UniProtKB).
GO:0043068;	Biological process: positive regulation of programmed cell death (inferred from direct assay from UniProtKB).
GO:0031398;	Biological process: positive regulation of protein ubiquitination (inferred from direct assay from UniProtKB).
GO:0046777;	Biological process: protein amino acid autophosphorylation (inferred from direct assay from UniProtKB).
GO:0007264;	Biological process: small GTPase mediated signal transduction (inferred from electronic annotation from InterPro).
QuickGo view.

Family and domain databases

InterPro

IPR011989; ARM-like.
IPR001611; Leu-rich_rpt.
IPR003591; Leu-rich_rpt_typical-subtyp.
IPR013684; Miro-like.
IPR000719; Prot_kinase_core.
IPR017441; Protein_kinase_ATP_BS.
IPR001806; Ras_GTPase.
IPR017442; Se/Thr_pkinase-rel.
IPR008271; Ser_thr_pkin_AS.
IPR005225; Small_GTP_bd.
IPR015943; WD40/YVTN_repeat-like.
IPR001680; WD40_repeat.
Graphical view of domain structure.

Gene3D

G3DSA:1.25.10.10; ARM-like; 1.
G3DSA:2.130.10.10; WD40/YVTN_repeat-like; 1.

Pfam

PF00560; LRR_1; 5.
PF08477; Miro; 1.
PF00069; Pkinase; 1.
Pfam graphical view of domain structure.

PRINTS

PR00449; RASTRNSFRMNG.

ProDom

PD000001; Prot_kinase; 2.
[Domain structure / List of seq. sharing at least 1 domain]

SMART

SM00369; LRR_TYP; 1.
SM00320; WD40; 1.
SMART graphical view of domain structure.

TIGRFAMs

TIGR00231; small_GTP; 1.

PROSITE

PS00107; PROTEIN_KINASE_ATP; 1.
PS50011; PROTEIN_KINASE_DOM; 1.
PS00108; PROTEIN_KINASE_ST; 1.
PS51424; ROC; 1.
PROSITE graphical view of domain structure (profiles).

Proteomic databases

PRIDE

Q5S007; -.

Genome annotation databases

Ensembl

ENSG00000188906; Homo sapiens. [Contig view]

GeneID

120892; -.

KEGG

hsa:120892; -.

Phylogenomic databases

HOGENOM

Q5S007; -.

HOVERGEN

Q5S007; -.

Other

80641; -.

LRRK2; Homo sapiens.

View cluster of proteins with at least 50% / 90% / 100% identity.

Keywords

3D-structure; Alternative splicing; ATP-binding; Coiled coil; Cytoplasm; Disease mutation; GTP-binding; GTPase activation; Kinase; Leucine-rich repeat; Membrane; Nucleotide-binding; Parkinson disease; Polymorphism; Repeat; Serine/threonine-protein kinase; Transferase.

Features

Feature table viewer

Feature aligner

`Key`	`From To`	`Length`	`Description`	`FTId`
`CHAIN`	`1 2527`	`2527`	`Leucine-rich repeat serine/threonine-protein kinase 2.`	`PRO_0000086238`
`REPEAT`	`226 249`	`24`	`LRR 1.`
`REPEAT`	`791 815`	`25`	`LRR 2.`
`REPEAT`	`981 1004`	`24`	`LRR 3.`
`REPEAT`	`1010 1033`	`24`	`LRR 4.`
`REPEAT`	`1035 1057`	`23`	`LRR 5.`
`REPEAT`	`1059 1081`	`23`	`LRR 6.`
`REPEAT`	`1082 1105`	`24`	`LRR 7.`
`REPEAT`	`1107 1127`	`21`	`LRR 8.`
`REPEAT`	`1128 1151`	`24`	`LRR 9.`
`REPEAT`	`1172 1194`	`23`	`LRR 10.`
`REPEAT`	`1195 1219`	`25`	`LRR 11.`
`REPEAT`	`1221 1243`	`23`	`LRR 12.`
`REPEAT`	`1244 1268`	`25`	`LRR 13.`
`REPEAT`	`1270 1291`	`22`	`LRR 14.`
`DOMAIN`	`1328 1511`	`184`	`Roc.`
`REPEAT`	`1556 1579`	`24`	`LRR 15.`
`REPEAT`	`1861 1887`	`27`	`LRR 16.`
`DOMAIN`	`1879 2138`	`260`	`Protein kinase.`
`NP_BIND`	`1341 1348`	`8`	`GTP (Potential).`
`NP_BIND`	`1885 1893`	`9`	`ATP (By similarity).`
`NP_BIND`	`2098 2121`	`24`	`GTP (Potential).`
`NP_BIND`	`2295 2298`	`4`	`GTP (Potential).`
`COILED`	`319 348`	`30`	`Potential.`
`COMPBIAS`	`728 731`	`4`	`Poly-Leu.`
`ACT_SITE`	`1994 1994`		`Proton acceptor (By similarity).`
`BINDING`	`1906 1906`		`ATP (By similarity).`
`VAR_SEQ`	`1 401`		`Missing (in isoform 2).`	`VSP_036140`
`VAR_SEQ`	`1260 1271`		`IPPEIGCLENLT -> VRRLLPLKKYTL (in isoform 2).`	`VSP_036141`
`VAR_SEQ`	`1272 2527`		`Missing (in isoform 2).`	`VSP_036142`
`VARIANT`	`50 50`	`1`	`H -> R (in dbSNP:rs2256408 [NCBI]).`	`VAR_024931`
`VARIANT`	`119 119`	`1`	`L -> P (in dbSNP:rs33995463 [NCBI]).`	`VAR_024932`
`VARIANT`	`228 228`	`1`	`C -> S (in dbSNP:rs56108242 [NCBI]).`	`VAR_054740`
`VARIANT`	`419 419`	`1`	`A -> V (in dbSNP:rs34594498 [NCBI]).`	`VAR_033903`
`VARIANT`	`551 551`	`1`	`N -> K (in dbSNP:rs7308720 [NCBI]).`	`VAR_024933`
`VARIANT`	`712 712`	`1`	`M -> V (in PD).`	`VAR_054741`
`VARIANT`	`716 716`	`1`	`A -> V.`	`VAR_054742`
`VARIANT`	`723 723`	`1`	`I -> V (in dbSNP:rs10878307 [NCBI]).`	`VAR_024934`
`VARIANT`	`755 755`	`1`	`P -> L (in dbSNP:rs34410987 [NCBI]).`	`VAR_033904`
`VARIANT`	`793 793`	`1`	`R -> M (in PARK8 and PD; idiopathic and late onset sporadic; could be a polymorphism; dbSNP:rs35173587 [NCBI]).`	`VAR_024935`
`VARIANT`	`871 871`	`1`	`K -> E.`	`VAR_054743`
`VARIANT`	`930 930`	`1`	`Q -> R (in PARK8; could be a poymorphism).`	`VAR_024936`
`VARIANT`	`944 944`	`1`	`D -> Y (in dbSNP:rs17519916 [NCBI]).`	`VAR_024937`
`VARIANT`	`1067 1067`	`1`	`R -> Q (in PD; familial nondominant).`	`VAR_024938`
`VARIANT`	`1096 1096`	`1`	`S -> C (in PARK8; could be a polymorphism).`	`VAR_024939`
`VARIANT`	`1122 1122`	`1`	`I -> V (in PARK8; dbSNP:rs34805604 [NCBI]).`	`VAR_024940`
`VARIANT`	`1228 1228`	`1`	`S -> T (in PARK8).`	`VAR_024941`
`VARIANT`	`1262 1262`	`1`	`P -> A (in dbSNP:rs4640000 [NCBI]).`	`VAR_024942`
`VARIANT`	`1371 1371`	`1`	`I -> V (in PARK8 and PD; could be a polymorphism; dbSNP:rs17466213 [NCBI]).`	`VAR_024943 [3D]`
`VARIANT`	`1375 1375`	`1`	`D -> E (in dbSNP:rs28365226 [NCBI]).`	`VAR_047022 [3D]`
`VARIANT`	`1398 1398`	`1`	`R -> H (in dbSNP:rs7133914 [NCBI]).`	`VAR_024944 [3D]`
`VARIANT`	`1441 1441`	`1`	`R -> C (in PARK8 and PD; autosomal dominant inheritance; show an increase in activity in both autophosphorylation and phosphorylation of a generic substrate).`	`VAR_024945 [3D]`
`VARIANT`	`1441 1441`	`1`	`R -> G (in PARK8 and PD; sporadic late-onset patients; dbSNP:rs33939927 [NCBI]).`	`VAR_024946 [3D]`
`VARIANT`	`1441 1441`	`1`	`R -> H (in PARK8 and PD; sporadic; pathogenicity has yet to be confirmed; dbSNP:rs34995376 [NCBI]).`	`VAR_024947 [3D]`
`VARIANT`	`1514 1514`	`1`	`R -> Q (in PARK8; pathogenicity has yet to be confirmed; might have an effect on protein structure; dbSNP:rs35507033 [NCBI]).`	`VAR_024948`
`VARIANT`	`1542 1542`	`1`	`P -> S (in PARK8; pathogenicity has yet to be confirmed; might have an effect on protein structure; dbSNP:rs33958906 [NCBI]).`	`VAR_024949`
`VARIANT`	`1550 1550`	`1`	`R -> Q (in an ovarian mucinous carcinoma sample; somatic mutation).`	`VAR_040678`
`VARIANT`	`1598 1598`	`1`	`V -> E (in PARK8; pathogenicity has yet to be confirmed; might have an effect on protein structure; dbSNP:rs721710 [NCBI]).`	`VAR_024950`
`VARIANT`	`1628 1628`	`1`	`R -> P (in dbSNP:rs33949390 [NCBI]).`	`VAR_024951`
`VARIANT`	`1646 1646`	`1`	`M -> T.`	`VAR_024952`
`VARIANT`	`1647 1647`	`1`	`S -> T (in dbSNP:rs11564148 [NCBI]).`	`VAR_024953`
`VARIANT`	`1699 1699`	`1`	`Y -> C (in PARK8; dbSNP:rs35801418 [NCBI]).`	`VAR_024954`
`VARIANT`	`1723 1723`	`1`	`R -> P (in an ovarian serous carcinoma sample; somatic mutation).`	`VAR_040679`
`VARIANT`	`1728 1728`	`1`	`R -> H (in PD).`	`VAR_054744`
`VARIANT`	`1728 1728`	`1`	`R -> L (in PD).`	`VAR_054745`
`VARIANT`	`1869 1869`	`1`	`M -> T (in PARK8 and PD; pathogenicity has yet to be confirmed).`	`VAR_024955`
`VARIANT`	`1870 1870`	`1`	`L -> F.`	`VAR_054746`
`VARIANT`	`1941 1941`	`1`	`R -> H (in PARK8).`	`VAR_024956`
`VARIANT`	`2012 2012`	`1`	`I -> T (in PARK8; pathogenicity uncertain).`	`VAR_024957`
`VARIANT`	`2019 2019`	`1`	`G -> S (in PARK8 and PD; idiopathic or sporadic; the most common genetic determinant of PD identified so far; show an increase in activity in both autophosphorylation and phosphorylation of a generic substrate).`	`VAR_024958`
`VARIANT`	`2020 2020`	`1`	`I -> T (in PARK8; significant increase in autophosphorylation of about 40% in comparison to wild-type protein in vitro).`	`VAR_024959`
`VARIANT`	`2081 2081`	`1`	`N -> D.`	`VAR_024960`
`VARIANT`	`2119 2119`	`1`	`P -> L (in dbSNP:rs12423862 [NCBI]).`	`VAR_024961`
`VARIANT`	`2141 2141`	`1`	`T -> M (in PD).`	`VAR_054747`
`VARIANT`	`2143 2143`	`1`	`R -> H (in PD).`	`VAR_054748`
`VARIANT`	`2261 2261`	`1`	`N -> I (in dbSNP:rs12581902 [NCBI]).`	`VAR_024962`
`VARIANT`	`2356 2356`	`1`	`T -> I (in PARK8).`	`VAR_024963`
`VARIANT`	`2385 2385`	`1`	`G -> R (associated with PD; both the wild-type and the variant protein localize to the cytoplasm and form aggregates; under conditions of oxidative stress the variant protein is more toxic and is associated with a higher rate of apoptosis; dbSNP:rs34778348 [NCBI]).`	`VAR_024964`
`VARIANT`	`2395 2395`	`1`	`E -> K.`	`VAR_054749`
`VARIANT`	`2397 2397`	`1`	`M -> T (in dbSNP:rs3761863 [NCBI]).`	`VAR_024965`
`VARIANT`	`2466 2466`	`1`	`L -> H (in PD).`	`VAR_054750`
`STRAND`	`1336 1341`	`6`
`HELIX`	`1347 1354`	`8`
`STRAND`	`1370 1377`	`8`
`STRAND`	`1389 1395`	`7`
`HELIX`	`1398 1402`	`5`
`HELIX`	`1406 1411`	`6`
`STRAND`	`1412 1420`	`9`
`HELIX`	`1421 1423`	`3`
`HELIX`	`1425 1429`	`5`
`HELIX`	`1431 1441`	`11`
`STRAND`	`1446 1452`	`7`
`HELIX`	`1454 1456`	`3`
`HELIX`	`1459 1472`	`14`
`TURN`	`1473 1475`	`3`
`STRAND`	`1481 1487`	`7`
`HELIX`	`1495 1509`	`15`

Sequence information

Length: 2527 AA [This is the length of the unprocessed precursor]

Molecular weight: 286058 Da [This is the MW of the unprocessed precursor]

CRC64: 6F6070F2437B9C06 [This is a checksum on the sequence]

        10         20         30         40         50         60 
MASGSCQGCE EDEETLKKLI VRLNNVQEGK QIETLVQILE DLLVFTYSEH ASKLFQGKNI 

        70         80         90        100        110        120 
HVPLLIVLDS YMRVASVQQV GWSLLCKLIE VCPGTMQSLM GPQDVGNDWE VLGVHQLILK 

       130        140        150        160        170        180 
MLTVHNASVN LSVIGLKTLD LLLTSGKITL LILDEESDIF MLIFDAMHSF PANDEVQKLG 

       190        200        210        220        230        240 
CKALHVLFER VSEEQLTEFV ENKDYMILLS ASTNFKDEEE IVLHVLHCLH SLAIPCNNVE 

       250        260        270        280        290        300 
VLMSGNVRCY NIVVEAMKAF PMSERIQEVS CCLLHRLTLG NFFNILVLNE VHEFVVKAVQ 

       310        320        330        340        350        360 
QYPENAALQI SALSCLALLT ETIFLNQDLE EKNENQENDD EGEEDKLFWL EACYKALTWH 

       370        380        390        400        410        420 
RKNKHVQEAA CWALNNLLMY QNSLHEKIGD EDGHFPAHRE VMLSMLMHSS SKEVFQASAN 

       430        440        450        460        470        480 
ALSTLLEQNV NFRKILLSKG IHLNVLELMQ KHIHSPEVAE SGCKMLNHLF EGSNTSLDIM 

       490        500        510        520        530        540 
AAVVPKILTV MKRHETSLPV QLEALRAILH FIVPGMPEES REDTEFHHKL NMVKKQCFKN 

       550        560        570        580        590        600 
DIHKLVLAAL NRFIGNPGIQ KCGLKVISSI VHFPDALEML SLEGAMDSVL HTLQMYPDDQ 

       610        620        630        640        650        660 
EIQCLGLSLI GYLITKKNVF IGTGHLLAKI LVSSLYRFKD VAEIQTKGFQ TILAILKLSA 

       670        680        690        700        710        720 
SFSKLLVHHS FDLVIFHQMS SNIMEQKDQQ FLNLCCKCFA KVAMDDYLKN VMLERACDQN 

       730        740        750        760        770        780 
NSIMVECLLL LGADANQAKE GSSLICQVCE KESSPKLVEL LLNSGSREQD VRKALTISIG 

       790        800        810        820        830        840 
KGDSQIISLL LRRLALDVAN NSICLGGFCI GKVEPSWLGP LFPDKTSNLR KQTNIASTLA 

       850        860        870        880        890        900 
RMVIRYQMKS AVEEGTASGS DGNFSEDVLS KFDEWTFIPD SSMDSVFAQS DDLDSEGSEG 

       910        920        930        940        950        960 
SFLVKKKSNS ISVGEFYRDA VLQRCSPNLQ RHSNSLGPIF DHEDLLKRKR KILSSDDSLR 

       970        980        990       1000       1010       1020 
SSKLQSHMRH SDSISSLASE REYITSLDLS ANELRDIDAL SQKCCISVHL EHLEKLELHQ 

      1030       1040       1050       1060       1070       1080 
NALTSFPQQL CETLKSLTHL DLHSNKFTSF PSYLLKMSCI ANLDVSRNDI GPSVVLDPTV 

      1090       1100       1110       1120       1130       1140 
KCPTLKQFNL SYNQLSFVPE NLTDVVEKLE QLILEGNKIS GICSPLRLKE LKILNLSKNH 

      1150       1160       1170       1180       1190       1200 
ISSLSENFLE ACPKVESFSA RMNFLAAMPF LPPSMTILKL SQNKFSCIPE AILNLPHLRS 

      1210       1220       1230       1240       1250       1260 
LDMSSNDIQY LPGPAHWKSL NLRELLFSHN QISILDLSEK AYLWSRVEKL HLSHNKLKEI 

      1270       1280       1290       1300       1310       1320 
PPEIGCLENL TSLDVSYNLE LRSFPNEMGK LSKIWDLPLD ELHLNFDFKH IGCKAKDIIR 

      1330       1340       1350       1360       1370       1380 
FLQQRLKKAV PYNRMKLMIV GNTGSGKTTL LQQLMKTKKS DLGMQSATVG IDVKDWPIQI 

      1390       1400       1410       1420       1430       1440 
RDKRKRDLVL NVWDFAGREE FYSTHPHFMT QRALYLAVYD LSKGQAEVDA MKPWLFNIKA 

      1450       1460       1470       1480       1490       1500 
RASSSPVILV GTHLDVSDEK QRKACMSKIT KELLNKRGFP AIRDYHFVNA TEESDALAKL 

      1510       1520       1530       1540       1550       1560 
RKTIINESLN FKIRDQLVVG QLIPDCYVEL EKIILSERKN VPIEFPVIDR KRLLQLVREN 

      1570       1580       1590       1600       1610       1620 
QLQLDENELP HAVHFLNESG VLLHFQDPAL QLSDLYFVEP KWLCKIMAQI LTVKVEGCPK 

      1630       1640       1650       1660       1670       1680 
HPKGIISRRD VEKFLSKKRK FPKNYMSQYF KLLEKFQIAL PIGEEYLLVP SSLSDHRPVI 

      1690       1700       1710       1720       1730       1740 
ELPHCENSEI IIRLYEMPYF PMGFWSRLIN RLLEISPYML SGRERALRPN RMYWRQGIYL 

      1750       1760       1770       1780       1790       1800 
NWSPEAYCLV GSEVLDNHPE SFLKITVPSC RKGCILLGQV VDHIDSLMEE WFPGLLEIDI 

      1810       1820       1830       1840       1850       1860 
CGEGETLLKK WALYSFNDGE EHQKILLDDL MKKAEEGDLL VNPDQPRLTI PISQIAPDLI 

      1870       1880       1890       1900       1910       1920 
LADLPRNIML NNDELEFEQA PEFLLGDGSF GSVYRAAYEG EEVAVKIFNK HTSLRLLRQE 

      1930       1940       1950       1960       1970       1980 
LVVLCHLHHP SLISLLAAGI RPRMLVMELA SKGSLDRLLQ QDKASLTRTL QHRIALHVAD 

      1990       2000       2010       2020       2030       2040 
GLRYLHSAMI IYRDLKPHNV LLFTLYPNAA IIAKIADYGI AQYCCRMGIK TSEGTPGFRA 

      2050       2060       2070       2080       2090       2100 
PEVARGNVIY NQQADVYSFG LLLYDILTTG GRIVEGLKFP NEFDELEIQG KLPDPVKEYG 

      2110       2120       2130       2140       2150       2160 
CAPWPMVEKL IKQCLKENPQ ERPTSAQVFD ILNSAELVCL TRRILLPKNV IVECMVATHH 

      2170       2180       2190       2200       2210       2220 
NSRNASIWLG CGHTDRGQLS FLDLNTEGYT SEEVADSRIL CLALVHLPVE KESWIVSGTQ 

      2230       2240       2250       2260       2270       2280 
SGTLLVINTE DGKKRHTLEK MTDSVTCLYC NSFSKQSKQK NFLLVGTADG KLAIFEDKTV 

      2290       2300       2310       2320       2330       2340 
KLKGAAPLKI LNIGNVSTPL MCLSESTNST ERNVMWGGCG TKIFSFSNDF TIQKLIETRT 

      2350       2360       2370       2380       2390       2400 
SQLFSYAAFS DSNIITVVVD TALYIAKQNS PVVEVWDKKT EKLCGLIDCV HFLREVMVKE 

      2410       2420       2430       2440       2450       2460 
NKESKHKMSY SGRVKTLCLQ KNTALWIGTG GGHILLLDLS TRRLIRVIYN FCNSVRVMMT 

      2470       2480       2490       2500       2510       2520 
AQLGSLKNVM LVLGYNRKNT EGTQKQKEIQ SCLTVWDINL PHEVQNLEKH IEVRKELAEK 


MRRTSVE

Q5S007 in FASTA format

View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry

	BLAST submission on ExPASy/SIB or at NCBI (USA)		Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
	ScanProsite, MotifScan		Submit a homology modeling request to SWISS-MODEL
	NPSA Sequence analysis tools